SCHEMBL18293123

SCHEMBL18293123

NCc1cnc2ccc3ccccc3c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PRMT5 O14744 1/20 0.42
PRMT3 O60678 1/20 0.42
CARM1 Q86X55 1/20 0.42
EHMT2 Q96KQ7 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT1 Q99873 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
CYP3A4 P08684 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GPR3 P46089 1/20 0.39
SLC2A1 P11166 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338300 0.77 ALDH1A1 (0.44) MAPTNPC1RECQLRAB9APRMT5
SCHEMBL29407958 0.77 ALDH1A1 (0.44) MAPTNPC1RECQLRAB9APRMT5
SCHEMBL28131480 0.75 ALDH1A1 (0.43) MAPTNPC1RECQLRAB9APRMT5
SCHEMBL23618591 0.74 NPC1 (0.46) MAPTLMNANPC1RECQLRAB9A
SCHEMBL17532740 0.74 MAPT (0.49) MAPTLMNANPC1RECQLRAB9A
SCHEMBL28088960 0.74 MAPT (0.46) MAPTLMNANPC1RECQLRAB9A
SCHEMBL4677179 0.72 PDE10A (0.69) MAPTLMNANPC1RAB9ALOXL2
SCHEMBL5470832 0.71 PRMT5 (0.56) MAPTLMNANPC1RECQLRAB9A
SCHEMBL31379757 0.71 SMN1; SMN2 (0.56) MAPTLMNANPC1RECQLRAB9A
SCHEMBL24596450 0.71 SMN1; SMN2 (0.56) MAPTLMNANPC1RECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303353-B1 PROCESS JOHNSON MATTHEY PLC (GB) 2022-01-12 EP disclosed
US-10428098-B2 Processes for preparing and using ruthenium and osmium complexes JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2019-10-01 US disclosed
WO-2019043414-A1 PROCESS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2019-03-07 WO disclosed
US-20180148465-A1 PROCESS UNIVERSITA DEGLI STUDI DI UDINE (IT) 2018-05-31 US disclosed
US-20180148465-A1 PROCESS UNIVERSITA DEGLI STUDI DI UDINE (IT) 2018-05-31 US disclosed
WO-2016193762-A1 PROCESS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428098-B2 Processes for preparing and using ruthenium and osmium complexes OSTC, OTC, ORC3 MAPT 3267/4885LMNA 4381/4885NPC1 1821/4885
US-20180148465-A1 PROCESS OSTC, AP2S1, LGALS4 MAPT 2770/4885LMNA 4467/4885NPC1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.